Ebola virus disease (EVD) is a severe and often fatal illness affecting humans and other primates. It is caused by an infection with one of a group of viruses known as ebolaviruses, which are found primarily in sub-Saharan Africa. Ebola is transmitted to people from wild animals such as fruit bats, and spreads in the human population through human-to-human transmission. The virus enters the body through cuts in the skin or when touching one’s eyes, nose, or mouth. Early symptoms include fever, fatigue, and headache. Ebola is spread through direct contact with body fluids such as blood, saliva, sweat, tears, mucus, vomit, feces, breast milk, urine, and semen of people infected with it. It is also spread by touching things that have been contaminated with these fluids. The average EVD case fatality rate is around 50%, and case fatality rates have varied from 25% to 90% in past outbreaks. There is no specific treatment for Ebola, but early supportive care with rehydration and symptomatic treatment improves survival. Two monoclonal antibodies (Inmazeb and Ebanga) were approved for the treatment of Zaire ebolavirus infection in adults and children by the US Food and Drug Administration in late 2020. A vaccine for Ebola was approved by the Food and Drug Administration in December 2019.